Recent News

Click here to join our mailing list for the latest news and updates

July 27, 2010

MABCURE ANNOUNCES POSITIVE RESULTS FOR NEW OVARIAN CANCER DIAGNOSTIC BLOOD TEST

» MORE

June 1, 2010

MEMORANDUM TO SHAREHOLDERS FROM DR. AMNON GONENNE, MABCURE’S CHIEF EXECUTIVE OFFICER

» MORE

March 31, 2010

MABCURE CEO ARTICLE FEATURED IN THE APRIL ISSUE OF "DRUG DISCOVERY NEWS"

» MORE

February 1, 2010

MABCURE FEATURED IN GENOMEWEB

» MORE

January 6, 2010

MABCURE LAUNCHES CLINICAL TRIAL TO DIAGNOSE OVARIAN CANCER

» MORE

November 4, 2009

MABCURE SIGNS RESEARCH AGREEMENT WITH BRUGGE, BELGIUM HOSPITAL

» MORE

September 29, 2009

MABCURE PRODUCES MONOCLONAL ANTIBODIES AGAINST COLORECTAL CANCER

» MORE

September 1, 2009

MABCURE CEO ARTICLE FEATURED IN THE SEPTEMBER ISSUE OF GENŽ

» MORE

August 25, 2009

MABCURE FEATURED IN BIOWORLDŽ TODAY

» MORE

August 18, 2009

ARTICLE BY MABCURE CEO -- TUMOUR-SPECIFIC MARKERS: THE HOLY GRAIL OF CANCER DIAGNOSTICSG

» MORE

August 7, 2009

MABCURE APPEARS IN ARTICLE ON "THE USE OF BIOMOLECULES IN DIAGNOSTIC TESTING

» MORE

MabCure, Inc.


MabCure is a biotechnology company whose vision is to change the perception of cancer as a largely incurable disease. MabCure's primary mission is to develop novel diagnostics for the early detection of cancer when the disease is still localized and treatable, and where the chances for cure are greater than 90 percent.

MabCure’s longer term goals are to provide physicians with novel antibodies and drugs that effectively attack only cancer cells while sparing normal tissue and minimize toxic side effects.

[Video] See President & CEO, Dr. Amnon Gonenne, talk about MabCure and its technology.